Physician profile
Amy Mehta
NPI 1942610977
$27,047.60
in general payments reported to CMS, 2019-2025
33 companies · $18K in 2025
The $18K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $631 · 2021: $1,216 · 2022: $2,119 · 2023: $2,694 · 2024: $1,798 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $5,657 · Consulting Fee: $2,300 · Travel and Lodging: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,800.00 |
| Food and Beverage | $5,656.69 |
| Consulting Fee | $2,300.00 |
| Travel and Lodging | $1,099.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,263.09 | 2022-2025 | |
| Alcon Vision LLC | $1,421.89 | 2021-2025 | Clareon, Simbrinza, Tryptyr |
| New World Medical,INC. | $927.07 | 2021-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Via360 |
| Allergan, INC. | $556.37 | 2020-2022 | |
| Glaukos Corporation | $477.28 | 2023-2025 | Idosetr, Idose |
| Aerie Pharmaceuticals, INC. | $404.08 | 2019-2021 | |
| Oyster Point Pharma, INC. | $386.29 | 2022-2025 | Tyrvaya, Ryzumvi |
| Ivantis, INC | $227.87 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $217.82 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Biotissue Holdings INC. | $199.01 | 2022-2024 | |
| Harrow Eye, LLC | $192.83 | 2024-2025 | Vevye, Ilevro |
| Ocular Therapeutix, INC. | $188.23 | 2022-2024 | Dextenza |
| Mallinckrodt Hospital Products INC. | $163.94 | 2024-2025 | Acthar |
| Rxsight INC | $156.65 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Carl Zeiss Meditec USA, INC. | $134.45 | 2023 | Artevo 800 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $121.74 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $121.70 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $118.22 | 2021-2022 | |
| Glaxosmithkline, LLC. | $117.08 | 2020 | |
| Sight Sciences, INC. | $85.48 | 2022-2024 | Omni Surgical System |
| Haag-Streit USA, INC. | $72.68 | 2025 | |
| Sun Pharmaceutical Industries INC. | $64.25 | 2022-2024 | |
| Dompe US, INC. | $62.07 | 2025 | Oxervate |
| Thea Pharma INC. | $61.41 | 2024-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $51.54 | 2020-2021 | |
| Rayner Intraocular Lenses Limited | $44.15 | 2022-2024 | Rayone Aspheric, Omidria, Rayone Emv |
| Beaver-Visitec International, INC. | $41.23 | 2022-2023 | |
| Alimera Sciences, INC. | $37.72 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $35.67 | 2021 | |
| Amgen INC. | $29.32 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $28.37 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.10 | 2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $17.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.